COVID-19 vaccines for high risk and immunocompromised patients

Charles S Pavia; Maria M Plummer

doi:10.1016/bs.mim.2021.11.001

COVID-19 vaccines for high risk and immunocompromised patients

Methods Microbiol. 2022:50:269-279. doi: 10.1016/bs.mim.2021.11.001. Epub 2022 Jan 28.

Authors

Charles S Pavia^{1

2}, Maria M Plummer³

Affiliations

¹ Department of Biomedical Sciences, NYIT College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, NY, United States.
² Division of Infectious Diseases, New York Medical College, Valhalla, NY, United States.
³ Department of Clinical Specialties, Division of Pathology, NYIT College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, NY, United States.

Abstract

The availability of multiple versions of vaccines designed to help prevent COVID-19 has offered an opportunity to at least control the current pandemic, and possibly to quickly eradicate this disease fully, along with the implementation of other preventive measures. In order to accomplish this feat more effectively, as many people as possible need to be vaccinated, especially for high-risk groups having co-morbid conditions such as diabetes, obesity and old age, and possibly those with various forms of immunodeficiencies, such as HIV/AIDS. This chapter focuses primarily on some of the basic biomedical aspects on vaccine design and use, and any possible concerns that need to be considered in getting people in the high-risk category vaccinated and monitored thereafter for their continuous health and well-being.

Keywords: AIDS patients; COVID-19 vaccines; Diabetes; HIV; Immunocompromised patients; Obesity; Risk groups; SARS-CoV-2; Vaccines.